Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients (TIMELY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01415011
Recruitment Status : Active, not recruiting
First Posted : August 11, 2011
Last Update Posted : May 10, 2018
Boehringer Ingelheim
Information provided by (Responsible Party):
University College, London

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Actual Primary Completion Date : August 2015
  Estimated Study Completion Date : September 2018